GlassScriptPhysician profile
Soumit K Basu
NPI 1467644377
$45,600.34
in general payments reported to CMS, 2019-2025
33 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $14K · 2021: $378 · 2022: $436 · 2023: $29.47 · 2024: $21.88 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $42,172.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $459.93 | 2019-2025 | Opdivo |
| Amgen INC. | $263.17 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $256.76 | 2019-2021 | |
| Daiichi Sankyo INC. | $251.49 | 2019-2025 | Datroway |
| Seagen INC. | $250.11 | 2019-2022 | |
| Janssen Biotech, INC. | $223.57 | 2019-2022 | |
| Genentech USA, INC. | $127.44 | 2019-2022 | |
| Beigene USA, INC. | $125.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $124.99 | 2019 | |
| Incyte Corporation | $113.48 | 2019-2025 | Jakafi |
| Exelixis INC. | $110.00 | 2019 | |
| Merck Sharp & Dohme LLC | $108.84 | 2020-2025 | Keytruda, Keytruda Qlex |
| Astellas Pharma US INC | $107.58 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $104.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.31 | 2020 | |
| Lilly USA, LLC | $84.96 | 2019 | |
| Eisai INC. | $80.71 | 2020 | |
| Argenx US, INC. | $78.48 | 2022 | |
| Janssen Scientific Affairs, LLC | $48.95 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $39.38 | 2022 | |
| Array Biopharma INC | $30.98 | 2025 | Xalkori, Braftovi, Xtandi |
| Tactile Systems Technology INC | $29.47 | 2023 | Flexitouch Plus, Entre Plus |
| Novartis Pharmaceuticals Corporation | $25.00 | 2022 | |
| Genzyme Corporation | $24.91 | 2022 | |
| Genmab U.S., INC. | $21.96 | 2025 | Epkinly |
| Tempus Ai, INC | $21.88 | 2024 | |
| Celgene Corporation | $18.84 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $18.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.18 | 2025 | |
| Seqirus USA INC | $15.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soumit Basu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.